CTX.TO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 15:58):

Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally...

Stats
Today's Volume	4 000.00
Average Volume	13 500.00
Market Cap	8.80M
EPS	$0 ( 2024-03-13 )
Next earnings date	( $0 ) 2024-05-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.40
ATR14	$0 (0.00%)

Crescita Therapeutics Inc Correlation

10 Most Positive Correlations
FM.TO	0.895
SKE.TO	0.869
HOT-UN.TO	0.859
CJR-B.TO	0.855
GOOS.TO	0.854
USA.TO	0.849
TNT-UN.TO	0.846
CRWN.TO	0.844
ERO.TO	0.837
JOY.TO	0.831

10 Most Negative Correlations
HAC.TO	-0.879
SFC.TO	-0.869
E.TO	-0.858
THNC.TO	-0.844
CIA.TO	-0.827
SBB.TO	-0.825
EMP-A.TO	-0.824
SJ.TO	-0.814
RQN.TO	-0.813
ATE.TO	-0.809

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Crescita Therapeutics Inc Financials

Annual	2023
Revenue:	$17.52M
Gross Profit:	$8.86M (50.55 %)
EPS:	$-0.0980

Q4	2023
Revenue:	$4.73M
Gross Profit:	$2.68M (56.74 %)
EPS:	$-0.00750

Q3	2023
Revenue:	$3.03M
Gross Profit:	$1.50M (49.42 %)
EPS:	$-0.0629

Q2	2023
Revenue:	$5.16M
Gross Profit:	$3.07M (59.45 %)
EPS:	$-0.0138

Financial Reports:

No articles found.

Crescita Therapeutics Inc

Crescita Therapeutics Inc., a dermatology company, provides non-prescription skincare products and prescription drug products in Canada, the United States, and internationally. The company operates through three segments: Commercial Skincare, Licensing and Royalties, and Manufacturing and Services. It owns proprietary platform technologies, including MMPE and DuraPeel for the development of topicals containing cannabis and hemp. The company's prescription products include Pliaglis, a topical local anesthetic cream that provides dermal analgesia on intact skin prior to superficial dermatological procedures; CTX-101, a Phase III topical formulation utilizing a corticosteroid in combination with MMPE technology to treat plaque psoriasis; CTX-102, a Phase I topical formulation utilizing MMPE technology to treat an undisclosed dermatological skin condition; and dermatology products in pre-clinical formulation utilizing MMPE technology for prescription treatments of skin diseases. Its non-prescription skincare products comprise skincare products, such as facial creams, cleansers, exfoliants, masks, serums, and suncare products for aging, acne, rosacea, pigmentation, dehydration, and sensitivity under the Laboratoire Dr Renaud brand; a line of dermocosmetic products for anti-aging medical procedures under the Pro-Derm brand; a line of products to target and treat various skincare concerns under the Alyria brand; and skincare products primarily for the Asian consumers under Dermazulene brand, as well as NCTF 135 HA, a skin revitalization solution primarily used for the improvement of skin quality and fine lines. The company has a development and licensing agreement with Sundial Growers Inc. to develop cannabis; a commercialization license agreement with Cantabria Labs Inc.; and a development and commercialization license agreement with Taro Pharmaceuticals Inc. Crescita Therapeutics Inc. was incorporated in 2016 and is headquartered in Laval, Canada.